Subscribe
Israel-Hamas Conflict
Donald Trump
Election Day
Fox News
US Economy
Kamala Harris
US Politics
Republican Party
US Crime
Netflix
US Immigration
Volleyball
Abortion
Published

Athos Announces Positive Topline Phase 1 Data For Its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion And Activation Of Potent Anti-Inflammatory Regulatory T Cells

Summary by pressreleasecc.com
ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activities No serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK)  The data provides clinical verification for Athos’ Proprietary AI2 (Artificial Intelligence …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Artificial IntelligenceArtificial Intelligence
Los Angeles, CaliforniaLos Angeles, California

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal